The BCL9-2 proto-oncogene governs estrogen receptor alpha expression in breast tumorigenesis

The majority of human breast cancers express estrogen receptor alpha (ER), which is important for therapy with anti-estrogens. Here we describe the role of BCL9-2, a proto-oncogene previously characterized as co-activator of Wnt/ß-catenin signaling, for mammary tumorigenesis in mice and human. ER positive human breast cancers showed overexpression of BCL9-2 and tamoxifen treated patients with high BCL9-2 demonstrated a better survival. BCL9-2 was upregulated during puberty and pregnancy in normal mammary epithelia, but downregulated in the involuted gland. BCL9-2 overexpression in vivo delayed the mammary involution and induced alveolar hyperplasia. Moreover, aged BCL9-2 transgenic mice developed ductal-like mammary tumors with high nuclear ER expression. We found, that primary cell cultures of BCL9-2 breast tumors responded to tamoxifen treatment. Moreover, BCL9-2 regulated the expression of ER and the proliferation of human breast cancer cells independently of ß-catenin. Finally, we describe a novel mechanism, how BCL9-2 regulates ER transcription by interaction with Sp1 through the proximal ESR1 gene promoter. In summary, BCL9-2 induces ER positive breast cancers in vivo, regulates ER expression by a novel ß-catenin independent mechanism in breast cancer cells, and might predict the therapy response to tamoxifen treatment.

[1]  Hans Clevers,et al.  Wnt/β-Catenin Signaling and Disease , 2012, Cell.

[2]  Kenny Q. Ye,et al.  Novel patterns of genome rearrangement and their association with survival in breast cancer. , 2006, Genome research.

[3]  R. Cardiff,et al.  Activation of β-catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[4]  T. Akiyama,et al.  Immunohistochemical expression of the β‐catenin‐interacting protein B9L is associated with histological high nuclear grade and immunohistochemical ErbB2/HER‐2 expression in breast cancers , 2007, Cancer science.

[5]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.

[6]  Harold E. Varmus,et al.  Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome , 1982, Cell.

[7]  A. Leong,et al.  The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment , 2011, Pathobiology.

[8]  K. Grandien.  Determination of transcription start sites in the human estrogen receptor gene and identification of a novel, tissue-specific, estrogen receptor-mRNA isoform , 1996, Molecular and Cellular Endocrinology.

[9]  Walter Birchmeier,et al.  Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. , 2006, Current opinion in genetics & development.

[10]  J. Gustafsson,et al.  The estrogen receptor gene: promoter organization and expression. , 1997, The international journal of biochemistry & cell biology.

[11]  M. Bienz,et al.  The function of BCL9 in Wnt/β-catenin signaling and colorectal cancer cells , 2008, BMC Cancer.

[12]  J. Bartek,et al.  Keratin 19 expression in the adult and developing human mammary gland , 1990, The Histochemical Journal.

[13]  K. Basler,et al.  Focus Review The many faces and functions of b-catenin , 2012 .

[14]  K. Brennan,et al.  Wnt Proteins in Mammary Development and Cancer , 2004, Journal of Mammary Gland Biology and Neoplasia.

[15]  R. Moll,et al.  CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions , 2002, Virchows Archiv.

[16]  F. Gannon,et al.  Human estrogen receptor-α: regulation by synthesis, modification and degradation , 2002, Cellular and Molecular Life Sciences CMLS.

[17]  F. Gannon,et al.  Minireview: genomic organization of the human ERalpha gene promoter region. , 2001, Molecular endocrinology.

[18]  S. Hilsenbeck,et al.  Sp1 is essential for estrogen receptor α gene transcription , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  R. Cardiff,et al.  Genetically Engineered Mouse Models of Mammary Intraepithelial Neoplasia , 2000, Journal of Mammary Gland Biology and Neoplasia.

[20]  A. Aboussekhra.  Role of cancer-associated fibroblasts in breast cancer development and prognosis. , 2011, The International journal of developmental biology.

[21]  C. Loddenkemper,et al.  WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer , 2013, EMBO molecular medicine.

[22]  Huaixing Li,et al.  Murine glypican-4 gene structure and expression; Sp1 and Sp3 play a major role in glypican-4 expression in 3T3-F442A cells. , 2004, Biochimica et biophysica acta.

[23]  D. Radisky,et al.  Mammary Involution and Breast Cancer Risk: Transgenic Models and Clinical Studies , 2009, Journal of Mammary Gland Biology and Neoplasia.

[24]  Eriko Suzuki,et al.  Wnt/beta-catenin and estrogen signaling converge in vivo. , 2004, The Journal of biological chemistry.

[25]  Shalom Madar,et al.  'Cancer associated fibroblasts'--more than meets the eye. , 2013, Trends in molecular medicine.

[26]  Alexander E. Kel,et al.  TRANSFAC® and its module TRANSCompel®: transcriptional gene regulation in eukaryotes , 2005, Nucleic Acids Res..

[27]  M. Lindstrom,et al.  ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Stevenson,et al.  Molecular and Cellular Determinants of Estrogen Receptor Expression , 2004 .

[29]  J. Lee,et al.  bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. , 1995, Cancer research.

[30]  Ole Winther,et al.  JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update , 2007, Nucleic Acids Res..

[31]  Lothar Hennighausen,et al.  Information networks in the mammary gland , 2005, Nature Reviews Molecular Cell Biology.

[32]  H. Varmus,et al.  Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  S. Fuqua,et al.  Regulation of the estrogen receptor alpha minimal promoter by Sp1, USF-1 and ERalpha. , 2004, Breast cancer research and treatment.

[34]  Ramon Kranaster,et al.  A non-canonical DNA structure is a binding motif for the transcription factor SP1 in vitro , 2011, Nucleic acids research.

[35]  S. Hayashi,et al.  Estrogen-related cancer microenvironment of breast carcinoma. , 2009, Endocrine journal.

[36]  H. Stevenson,et al.  Molecular and cellular determinants of estrogen receptor alpha expression. , 2004, Molecular and cellular biology.

[37]  T. Dale,et al.  Wnt signalling in murine postnatal mammary gland development , 2012, Acta physiologica.

[38]  M. Bienz,et al.  Pygopus and Legless target Armadillo/β-catenin to the nucleus to enable its transcriptional co-activator function , 2004, Nature Cell Biology.

[39]  M. Edery,et al.  The lack of effect of phenol red or estradiol on the growth response of human, rat, and mouse mammary cells in primary culture. , 1988, Endocrinology.

[40]  A. J. Valente,et al.  Regulation of the Estrogen Receptor α Minimal Promoter by Sp1, USF-1 and ERα , 2004, Breast Cancer Research and Treatment.

[41]  M. Delorenzi,et al.  Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. , 2010, Cancer research.

[42]  X. Dai,et al.  Chromatin effector Pygo2 regulates mammary tumor initiation and heterogeneity in MMTV-Wnt1 mice , 2013, Oncogene.

[43]  M. Abdelrahim,et al.  Sp transcription factor family and its role in cancer. , 2005, European journal of cancer.

[44]  F. Gannon,et al.  Human estrogen receptor-alpha: regulation by synthesis, modification and degradation. , 2002, Cellular and molecular life sciences : CMLS.

[45]  Walter Birchmeier,et al.  Balancing cell adhesion and Wnt signaling, the key role of β-catenin , 2006 .

[46]  L. Donehower,et al.  P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis , 2011, Breast Cancer Research and Treatment.

[47]  Jie Tian,et al.  Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. , 2009, Cancer research.

[48]  Jungsuk An,et al.  Epithelial–mesenchymal transition in breast cancer correlates with high histological grade and triple‐negative phenotype , 2012, Histopathology.

[49]  Patrick Franken,et al.  A Targeted Constitutive Mutation in the Apc Tumor Suppressor Gene Underlies Mammary But Not Intestinal Tumorigenesis , 2009, PLoS genetics.

[50]  V. Band,et al.  Mouse models of estrogen receptor-positive breast cancer , 2011, Journal of carcinogenesis.

[51]  H. Varmus,et al.  Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice , 1988, Cell.

[52]  Martin Koš,et al.  0888-8809/01/$03.00/0 Molecular Endocrinology 15(12):2057–2063 Printed in U.S.A. Copyright © 2001 by The Endocrine Society Minireview: Genomic Organization of the Human ER � Gene Promoter Region , 2022 .

[53]  F. Brembeck,et al.  Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions. , 2004, Genes & development.

[54]  H. Varmus,et al.  A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. , 1999, Cancer research.

[55]  F. Brembeck,et al.  BCL9-2 promotes early stages of intestinal tumor progression. , 2011, Gastroenterology.

[56]  Barry Komm,et al.  Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. , 2003, Endocrinology.

[57]  I. Treilleux,et al.  A transcriptional enhancer required for the differential expression of the human estrogen receptor in breast cancers , 1997, Molecular and cellular biology.

[58]  A. Howell,et al.  A putative human breast stem cell population is enriched for steroid receptor-positive cells. , 2005, Developmental biology.

[59]  R. Kucherlapati,et al.  Genetic Mechanisms in Apc-Mediated Mammary Tumorigenesis , 2009, PLoS genetics.

[60]  M. Imamura,et al.  Mechanisms of estrogen receptor-α upregulation in breast cancers , 2010, Medical Molecular Morphology.

[61]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  P. Cowin,et al.  Key signaling nodes in mammary gland development and cancer: β-catenin , 2010, Breast Cancer Research.

[63]  H. Varmus,et al.  A Mouse Mammary Tumor Virus-Wnt-1 Transgene Induces Mammary Gland Hyperplasia and Tumorigenesis in Mice Lacking Estrogen Receptor-α , 1999 .

[64]  Y. Kawasaki,et al.  Wnt/β-Catenin and Estrogen Signaling Converge in Vivo* , 2004, Journal of Biological Chemistry.

[65]  R. Fodde,et al.  Wnt/beta-catenin signaling in cancer stemness and malignant behavior. , 2007, Current opinion in cell biology.

[66]  Sandipan Chatterjee,et al.  Wnt/wingless Signaling Requires Bcl9/legless-mediated Recruitment of Pygopus to the Nuclear Beta-catenin-tcf Complex , 2022 .

[67]  Riccardo Fodde,et al.  Wnt/β-catenin signaling in cancer stemness and malignant behavior , 2007 .

[68]  S. Hilsenbeck,et al.  Sp1 is essential for estrogen receptor alpha gene transcription. , 2002, The Journal of steroid biochemistry and molecular biology.

[69]  J. Gustafsson,et al.  The different roles of ER subtypes in cancer biology and therapy , 2011, Nature Reviews Cancer.